

NEUROLOGY RESUME

AUDRIUS V. PLIOPLYS, MD, FRCPC

Revised August 5, 2016

EMAIL: plioplysav@sbcglobal.net

WEBSITE: www.plioplys.com

BORN: September, 1951, Toronto, Ontario, Canada

RESIDENCE: Chicago, Illinois

CITIZENSHIP: United States and Canada

EDUCATION:

High School: St. Rita High School, Chicago, Illinois
Graduated Valedictorian, June 1968
National Merit Semifinalist

College: University of Chicago
Majors of Physics and Chemistry
September 1968 to June 1971
Dean's List for superior academic performance
GPA in the Summa Cum Laude range

Medical School: Pritzker School of Medicine
University of Chicago
Graduated with MD degree June 1975

POST-GRADUATE EDUCATION:

Adult Internal Medicine: University of Wisconsin Hospitals, Madison, Wisconsin; June 1975 to June 1976 (one year).

Adult Neurology: Mayo Clinic, Rochester, Minnesota; June 1979 to June 1980, and June 1981 to June 1982 (two years).

Electromyography: Mayo Clinic, Rochester, Minnesota; January through June 1982 (under supervision of Dr. Jasper Daube—subsequently Chairman, Department of Neurology, Mayo Clinic, and President, American Academy of Neurology).

General Pediatrics: Mayo Clinic, Rochester, Minnesota; June 1980 to June 1981 (one year).

General Pediatrics, Core II level: Hospital for Sick Children, Toronto, Ontario; June 1982 to June 1983 (one year).

Chief Resident in Pediatric Neurology: Hospital for Sick Children, Toronto, Ontario; June 1983 to June 1984 (one year).

Research Fellowship in Neuroimmunology (funded by the Medical Research Council of Canada) with Dr. R.B. Hawkes, Laval University, Quebec City, June 1984 to June 1986 (two years).

POST-GRADUATE EDUCATION (ADDITIONAL DETAILS):

Neonatology:

During the pediatrics residencies at the Mayo Clinic and at the Hospital for Sick Children, the total amount of hands-on neonatology (NICU) experience is approximately equivalent to 2 years of current neonatology residency.

Neuroradiology:

When the first CT head scanner was delivered to North America, at the Montreal Neurological Institute, I arranged for a medical student clerkship in Montreal to become acquainted with this new technology (autumn, 1974). As part of ongoing residency training, subsequent clinical practice, following the neurological medical literature, and attendance at neurology and child neurology national and international meetings, it has been readily possible to continue being up-to-date with all subsequent CT and MRI technological advances, and their clinical applications.

Neurology research:

Before starting medical school, I was strongly committed to medical research: during that summer I worked in the neurobiology research laboratory at the University of Chicago, and shortly published my first research article in 1972. This commitment to advance the health of the patients that I take care of, has actively continued, on a daily basis, throughout medical school, all aspects of post-graduate education, and all aspects of subsequent medical work. The numbers of publications, presentations, awards, and grants received attest to this strong life-long commitment to medical research and to the advancement of curing illness.

POST-GRADUATE EDUCATION (SUPPLEMENTAL):

June 1976 to June 1979: Independent study of art and art history, Washington, D.C. For details concerning my art exhibits, art reviews about my art work, and art historical publications, please see my art resume which is available at www.plioplys.com.

PRESENT POSITION:

I retired from clinical practice on January 1, 2009, but have continued my involvement in child neurology in the areas of research, consulting, peer-reviewing of articles and grant applications, writing articles, and teaching.

PREVIOUS POSITIONS:1986 through 1989:

Neurology Staff, Division of Neurology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.

Assistant Professor, Department of Neurology, University of Toronto, Toronto, Ontario, Canada.

Project Director Surrey Place Center Toronto, Ontario, Canada.

Project Director, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.

1990 through 1991:

Director Child Neurology, Michael Reese Hospital, Chicago, Illinois.

Director Alzheimer's Disease Center, Michael Reese Hospital, Chicago, Illinois.

1990 through 2002:

Medical Director and Attending Physician, Philip J. Rock School and Center, Glen Ellyn, Illinois, a residential center for 25 children who are deaf and blind, who require constant skilled nursing attention.

1990 through 2004:

Adult and Child Neurology Staff, Michael Reese Hospital, Chicago, Illinois.

1990 through 2005:

Medical Director and Attending Physician, Little Angels Nursing Home, Elgin, Illinois; pediatric skilled nursing facility for 58 children and young adults with severe neurologic disabilities.

1990 through 2008:

Director, Child Neurology, Advocate Health Care Plans (originally Michael Reese Health Care Plan) Chicago, Illinois.

Neurology Staff, Department of Neurology, Mercy Hospital, Chicago, Illinois.

Medical Director and Attending Physician: Marklund Children's Nursing Home, Bloomingdale, Illinois; pediatric skilled nursing facility for 100 children with severe neurologic disabilities (in 2004 the facility was downsized to 30 residents).

1991 through 1996:

Director Alzheimer's Disease Center, Mercy Hospital, Chicago.

1991 through 1998:

Assistant Professor, Department of Neurology, University of Illinois.

1993 through 2001:

Director, Chronic Fatigue Research Center, Mercy Hospital, Chicago, Illinois.

Medical Director and Attending Physician, Alden Village, Bloomingdale, Illinois; pediatric skilled nursing facility for 100 children and young adults with severe neurologic disabilities.

1996 through 2005:

Medical Director and Attending Physician, Genesis House, Genoa, Illinois; skilled nursing facility for 100 young adults with developmental neurologic disabilities (in 2003 the number was downsized to 62 residents).

1999 through 2003:

Medical Director and Attending Physician, Mosaic Living Center, Chicago, Illinois; pediatric skilled nursing facility for 85 children and young adults with severe neurologic disabilities.

2002 through 2007:

Medical Director and Attending Physician, Meadows, Rolling Meadows, Illinois; skilled nursing facility for 100 young adults with developmental neurologic disabilities.

Chairman Research Review Committees, National Institutes of Health, Bethesda, MD (1994):

1. Neuroimmunology of Autism;
2. Neuroimmunology of Alzheimer's Disease.

Chairman Research Review Committee, Food and Drug Administration, Rockville, MD (1996): Neurology Panel, Orphan Products Development Grant Program.

Founder and Past-Chairman, Pediatric Long Term Care Section, American Medical Directors Association (1997-2005).

Member, House of Delegates, American Medical Directors Association (1997-2005).

Lecturer and instructor, Certified Medical Director (CMD) certification program for specialist physicians, American Medical Directors Association.

Liaison Representative from the American Medical Directors Association to the American Academy of Pediatrics (1998-2005).

Member, Committee for Home Health Care, American Academy of Pediatrics (1998-2005).

Member, Task Force for Standards of Care for Pediatric Nursing Facilities (14-member nationwide task force headed by Sister Katherine Smith, Portland, Oregon; 2000-2005).

Peer Review Consultant for the development of clinical practice guidelines: "Pharmacological Treatment of Spasticity in Children and Adolescents with Cerebral Palsy", American Academy of Neurology and the Child Neurology Society (2008-2009)

Examiner in child neurology for the American Board of Psychiatry and Neurology.

Peer Review Consultant, Practice Committee of the Child Neurology Society, for practice parameters in the diagnostic assessment of children with cerebral palsy, and for practice parameters in the pharmacologic treatment of spasticity in children and adolescents with cerebral palsy.

Peer Review Consultant, National Institutes of Health, Bethesda, Maryland.

Peer Review Consultant, Food and Drug Administration, Rockville, Maryland.

Peer Review Consultant, Wellcome Trust, London, United Kingdom.

Peer Review Consultant, United States Air Force Office of Scientific Research, Arlington, Va.

Clinical Consultant to the immunization-reaction program, United States Department of Justice, Washington, D.C.

Peer reviewer for the journals:

Archives of Pediatrics and Adolescent Medicine

Autism

Biological Psychiatry

European Journal of Epidemiology

Human Immunology

Journal of the American College of Nutrition

Journal of Autism and Developmental Disorders

Journal of Internal Medicine

Journal of Pediatrics

Journal of Psychosomatic Medicine

Lancet (Neurology)

Neurologijos Seminarai (Lithuania)

Pediatrics

Southern Medical Journal

EXPERIENCE IN PEDIATRIC AND ADULT LONG-TERM CARE:

As the Medical Director and Attending Physician of many skilled nursing facilities, the number of full-time (24 hours per day, 7 days per week), years of patient care, from November 1990 through January 1, 2009 is:

Pediatric and young adult	4,048
Adult:	1,430
Total:	<u>5,478</u>

The cited years of pediatric and young adult long-term care experience, with severely neurologically disabled individuals, most likely exceeds that of any physician in North America.

Founder and Chairman (for 8 years, through 2005), Pediatric Long-Term Care Section, American Medical Directors Association. In that capacity, organized 8 years of multi-day pediatric long-term care conferences as part of the annual AMDA meetings, attracting conference presenters and attendees from across North America.

Extensive clinical research programs and publications to advance the health care needs of severely disabled children and young adults including:

- Treatment of Rett Syndrome,
- Identification and treatment of unrecognized carnitine deficiency,
- Use of the Ketogenic diet to treat epilepsy,
- Use of new anticonvulsants to treat epilepsy,
- Methods for the assessment of disuse osteoporosis,
- Defining risk factors for the development of osteoporosis,
- Methods for the prevention and treatment of osteoporosis,
- Prevention of pneumonias with vest therapy programs,
- Prevention of pneumonias through the use of intermittent inhaled antibiotics,
- Improvement in the evaluation and treatment of cerebral palsy spasticity.

As the Chairman of the Pediatric Long-Term Care Section of the American Medical Directors Association, introduced two House of Delegates resolutions that were accepted unanimously:

F99, March 1999, "Be it resolved, that the American Medical Directors Association work to encourage accreditation and regulatory agencies to work with the American Medical Directors Association Pediatric Long Term Care Section, other qualified physicians and interdisciplinary professionals to modify guidelines to be age specific regarding pediatric long term care."

G00, March 2000, "Be it resolved, that the American Medical Directors Association opposes any physician involvement in assisted suicide or active euthanasia of any person regardless of age."

EXPERIENCE IN PEDIATRIC LONG-TERM CARE (OF NOTE):

Best reported survival rates of severely disabled children in the world's medical literature (articles 45, 53, 55, 56, 57, and 59).

PROFESSIONAL CERTIFICATES:

Successfully completed the specialty examination in Neurology with special competence in Child Neurology of the Royal College of Physicians and Surgeons of Canada, November, 26, 1984.

Board Certified in Neurology with special competence in Child Neurology by the American Board of Psychiatry and Neurology, November, 1986; certificate #300593.

Board eligible in Pediatrics by the American Board of Pediatrics.

Examiner in child neurology for the American Board of Psychiatry and Neurology.

PROFESSIONAL MEMBERSHIPS:

American Academy of Neurology

Child Neurology Society

Society for Neuroscience

Royal College of Physicians and Surgeons of Canada (Fellow: FRCPC)

American Academy of Pediatrics (Fellow: FAAP; retired)

American Medical Directors Association (Certified Medical Director: CMD; retired)

American College of Nutrition (Fellow: FACN; retired)

International Child Neurology Association (retired)

International Neuropsychiatry Association (retired)

MEDICAL LICENSURE

Illinois (#036-079654)

Indiana (#01038136)

FELLOWSHIPS AND GRANTS:

Research fellowship in neurochemistry (Dr. Cutler's laboratory, University of Chicago; research in blood-brain-barrier physiology) funded by the National Institutes of Health, summer 1971.

Research fellowship in neurophysiology (Dr. Goldberg's laboratory, University of Chicago; neurophysiology of the trapezoid body in cats) funded by the National Institutes of Health, summer 1972.

Research fellowship Parkinson's Disease Foundation (Dr. Mullan's laboratory, University of Chicago; research in catecholamine changes in head trauma and protective effects of DMSO), 1972-3.

Cerebrovascular Disease Fellowship, Mayo Clinic, Rochester, Minnesota, funded by the American Heart Association, summer 1974.

Advanced studies in neuroradiology and electroencephalography at the Montreal Neurological Institute, autumn 1974.

The Mayo Clinic Foundation approved and funded grant application to study cerebrospinal fluid substance P, CCK and VIP concentrations (1981-2).

Medical Research Council of Canada research fellowship in neuroimmunology, at Laval University with Dr. Richard Hawkes, Quebec City, Canada, from June 1984 to June 1986.

The Physician Services Inc. Foundation has awarded a two year, \$69,000 grant for the study of anti-central nervous system antibody activity in childhood neurologic disorders (1987-8).

Ontario Mental Health Foundation awarded a two year \$118,000 grant for the Neurobiology of Alzheimer's Disease (1989).

Illinois Department of Public Health awarded a one year \$19,000 grant for the Neurobiology of Alzheimer's Disease (1990-1).

Medical Research Institute Council of Michael Reese Hospital awarded a \$62,000 grant for the Neurobiology of Alzheimer's Disease (1990-1).

Hoechst-Roussel Pharmaceutical Co. awarded a one year, \$31,400 grant for the clinical investigation of HP029 (velnacrine maleate) as a treatment of Alzheimer's Disease (1991).

Sigma-Tau Pharmaceutical Co. awarded a one year \$32,000 grant (including medication supplies) for the investigation of L-carnitine and amantadine for the treatment of Chronic Fatigue Syndrome (1993-4).

Chronic Fatigue Syndrome Association of Minnesota awarded a one year, \$10,000 grant for an investigation entitled: "Electron microscopic investigation of muscle mitochondria in CFS". Additional support of \$6,000 was received for this project from Sigma-Tau Pharmaceutical Co. (1994).

National Institutes of Health, **\$2.4 million grant**, "Estimating Rates of CFS in a Community Sample", with co-primary investigator, Dr. Leonard Jason, Chairman, Department of Psychology, DePaul University, Chicago, Illinois. (1995-2000). This grant application received a priority rating of 115 with 100 being a perfect score and 500 being the lowest acceptable score. This result placed the scientific merit of our proposal in the top 1 percentile of all NIH grant applications. This high of an evaluation result is almost unheard of in the medical research community.

American Biosystems Incorporated awarded a two-year, \$35,000 grant to support the activities of the Pediatric Long-Term Care Section of the American Medical Directors Assoc. (2000-1).

Advanced Respiratory Incorporated awarded a two-year, \$30,000 grant to support the activities of the Pediatric Long-Term Care Section of the American Medical Directors Assoc. (2001-2).

STATE OF ILLINOIS ADVANCED DIRECTIVES

On September 27, 1990, I testified in court concerning the neurologic status and prognosis of Mr. Greenspan, an unfortunate individual with advanced Alzheimer's Disease and superimposed strokes. He was in a persistent vegetative state, and was being maintained with naso-gastric tube feedings, since 1985. The next day, Judge Richard Dowdle allowed the family's request to remove the feeding tube, and Mr. Greenspan passed away within a week. This case received a great deal of media attention and motivated the government of the State of Illinois to introduce legislation about advanced directives. My appearance at this trial was pivotal in having advanced directive legislation introduced and passed in Illinois. My appearance was mentioned in the Chicago Sun-Times, September 28, 1990, page 14.

HONORS AND AWARDS:

Graduated high school as valedictorian (highest academic ranking from among a graduating class of 450 students), and National Merit Semifinalist, June 1968.

University of Chicago college GPA in the Summa Cum Laude range.

Dean's List (indicative of superior academic achievement) in college at the University of Chicago during the academic years of 1968-9 and 1970-1, two of the three years in college.

Teaching assistantship in neuroanatomy, University of Chicago, spring 1975.

Award for best research and best presentation at the Northwestern Pediatric Society meeting, Minneapolis, Minnesota, September 25, 1981.

Invited visiting professor of neurology and neuroscience, University of Vilnius, Lithuania, May, 1989.

Invited to chair research review committee: neuroimmunology of autism; National Institutes of Health, Bethesda, Maryland, July, 1994.

Invited to chair research review committee: neuroimmunology of Alzheimer's Disease; National Institutes of Health, Bethesda, Maryland, July, 1994.

Invited to chair faculty review committee for the Department of Neurology, University of Jordan, Amman, Jordan, January, 1995.

Invited to chair research review committee: Neurology Panel, Orphan Products Development Grant Program, Food and Drug Administration, Rockville, Maryland, December 1996.

Invited to consult to the immunization-reaction program, U.S. Department of Justice, Washington, D.C. Duties include reviewing the medical history and examining children who may have had immunization-related neurologic injuries, February, 1997.

Invited visiting professor of child neurology, University of Jordan, Amman, Jordan, and the Jordan Pediatrics Society, May, 1997.

Chronic Fatigue Syndrome Center mentioned as part of a Gubernatorial Proclamation by Governor Jim Edgar, Governor of the State of Illinois, February 14, 1994.

Television interview, Channel 2 News, Chicago, Illinois, Chronic Fatigue Syndrome with Dr. Terri Hamilton, May 13, 1994.

Television interview, Chronic Fatigue Syndrome, CLTV News, Chicago, Il., September 20, 1994.

Listed in the Marquis publications: Who's Who in the Midwest, Who's Who in the World, Who's Who in Medicine and Health Care and Canadian Who's Who.

Second place award from the American Medical Directors Association for poster presentation "Osteoporosis in Pediatric Long-Term Care", March, 2000, during the annual meeting of AMDA in San Francisco, California. There were a total of 76 medical research posters presented.

Plaque recognizing contributions to Pediatric Long Term Care by the Board of Directors of the American Medical Directors Association, March, 2003.

Radio interview, "Autoimmune Hypothesis as a Cause of Autism," Autism One Radio, October 18, 2005. The audio of this interview can be found in the archives section of www.autismone.org.

Repeatedly invited to be an examiner in child neurology for the American Board of Psychiatry and Neurology.

Selected to be one of "America's Top Physicians" 2004 through 2010, by the Consumers' Research Council of America.

Man of the Year Award, December, 2011, from the Balzekas Museum of Lithuanian Culture, Chicago, Illinois, for work done in the American-Lithuanian community, in particular for organizing the 70-year commemoration of the suffering and deaths of tens of millions of Eastern Europeans at the hands of Stalin. The Hope and Spirit project was a full year program of exhibits, lectures, performances, book signings, film viewings, poetry readings, and personal presentations by deported individuals. The program has been summarized on the project's website: www.HOPEandSPIRIT.net.

INVITED LECTURES:

Invited lecturer, "Kernicterus", Fourth Lithuanian Symposium of the Arts and Sciences, Chicago, Illinois, November 26, 1981.

Invited lecturer, "Mental Retardation: Selected Biologic and Diagnostic Aspects", Chicago Medical Society, Chicago, Illinois, March 14, 1982.

Invited lecturer, "Monoclonal Antibodies and the Central Nervous System", Fifth Lithuanian Symposium of the Arts and Sciences, Chicago, Illinois, November 29, 1985.

Invited lecturer, "Neurobiology of Down Syndrome: Recent Research Advances":
 Ontario Chapter of the American Association on Mental Retardation,
 London, Ontario, Canada, March 12, 1987.
 Department of Genetics Grand Rounds, Hospital for Sick Children, Toronto,
 Canada, April 23, 1987.
 Membrane Seminar, Hospital for Sick Children Research Institute,
 June 26, 1987.
 Ontario Chapter of the American Association on Mental Retardation,
 Toronto, Canada, March 3, 1988.
 Department of Pediatrics Grand Rounds, Hospital for Sick Children, Toronto,
 Canada, September 19, 1988.

Invited lecturer research conference on autism, Goteborg, Sweden, May 7-10, 1989.

Invited lecturer, "Research Advances in Autism":
 Ontario Chapter of the American Association on Mental Retardation,
 Toronto, Canada, March 9, 1989.
 Toronto Neurology Update Symposium, University of Toronto, Toronto,
 Canada, June 9, 1989.
 Illinois Chapter of Autism Society of America, Schaumburg, Illinois,
 June 25, 1992.
 Kennedy Krieger Institute, Johns Hopkins Hospital, Baltimore, Maryland,
 April 3, 1998.

Invited lecturer, "Autism: Clinical Review and Autoimmune Hypothesis":
 National Naval Medical Center, Bethesda, Maryland, June 12, 1999
 Conference organized by MAT (Medicine for Autism Today).
 Cure Autism Today (CAN) Illinois Chapter, St. Charles, Illinois,
 September 26, 1999.
 Autism and Epilepsy Think Tank Meeting, Standard Club, Chicago, Illinois,
 April 10, 2000.

Invited lecturer, "Research in Alzheimer's Disease: New Perspectives":
 Department of Neurology, Grand Rounds, Michael Reese Hospital, Chicago,
 Illinois, February 20, 1990.

Holy Cross Hospital, Grand Rounds, Chicago, Illinois, February 6, 1991.
 Mercy Hospital and Medical Center, Grand Rounds, Chicago, Illinois,
 April 5, 1991.
 Michael Reese Hospital, "Alzheimer's Disease Symposium", Chicago, Il.,
 April 21, 1990.
 Mercy Hospital, Chicago, Illinois, June 20, 1992.
 Mercy Hospital, Chicago, Illinois, November 6, 1992.
 Mercy Medical on Pulaski, Chicago, Illinois, November 3, 1993.
 Mercy Health Care and Rehabilitation Center, Homewood, Illinois,
 November 11, 1993.
 Mercy Medical on Pulaski, Chicago, Illinois, November 2, 1994.
 Mercy Health Care and Rehabilitation Center, Homewood, Illinois,
 November 16, 1994.

Invited lecturer, "Epilepsy: Causes and Treatment":

Philip J. Rock Center and Illinois Interagency Agreement Committee,
 Chicago, Illinois, May 28, 1993.

Philip J. Rock Center Conference, Chicago, Illinois, June 6, 1993.

Invited lecturer, "Recent Advances in the Diagnosis and Treatment of Individuals with
 Developmental Disabilities":

Ludeman Developmental Center, Park Forest, Illinois, November 23, 1992.

Glenwood Developmental Center, Glenwood, Iowa, December 4, 1992.

Moose Lake Developmental Center, Moose Lake, Minnesota, March 5, 1993.

Faribault State Hospital, Faribault, Minnesota, March 6, 1993.

Shapiro Developmental Center, Kankakee, Illinois, March 19, 1993.

New Castle State Developmental Center, New Castle, Ind., July 14, 1993.

Singer Developmental Center, Rockford, Illinois, September 24, 1993.

Jacksonville Developmental Center, Jacksonville, Illinois, August 15, 1997.

Lincoln Developmental Center, Lincoln, Illinois, August 15, 1997.

Invited lecturer, "Chronic Fatigue Syndrome: Clinical and Research Perspectives":

CFS Society of Illinois, Chicago, Illinois, August 1, 1993.

Mercy Hospital and Medical Center, Grand Rounds, Chicago, Illinois,
 April 15, 1994.

University of Illinois, Department of Neurology, Grand Rounds, Chicago, Il.
 May 20, 1994.

CFS Society of Illinois, Chicago, Illinois, January 8, 1995.

Chicago Medical Society, 1995 Midwest Clinical Conference, Chicago, Il.,
 Jan. 22, 1995.

Michael Reese Hospital, Department of Medicine, Grand Rounds, Chicago, Il.,
 January 15, 1998.

Invited lecturer, "Mitochondria, Carnitine and Chronic Fatigue Syndrome", American College
 of Nutrition annual meeting, San Francisco, CA, October 13, 1996.

Invited lecturer, "Clinical Research Advances in Pediatric Skilled Nursing Facilities":
 Care of the Medically Fragile Child in the New Millennium, Seekonk,
 Massachusetts, May 4, 2000 (keynote speech).
 Rehabilitation Institute of Chicago, Grand Rounds, May 10, 2000.

Invited lecturer, "Survival Rates of Children with Severe Neurologic Disabilities in Pediatric Skilled Nursing Facilities":
 American Medical Directors Association, Annual Meeting, Phoenix, Arizona,
 February 16, 1997.
 Developmental Disabilities Nursing Association, Hillside, IL, May 7, 1997.
 Illinois Health Care Association, Bloomingdale, IL, May 8, 1997.
 Care of the Medically Fragile Child, Providence Health System, Portland,
 Oregon, September 26, 1997.
 Department of Pediatrics, University of Arizona, Phoenix, Arizona,
 October 31, 1997.
 Child Neurology Society annual meeting, Pediatric Neurorehabilitation Section,
 Washington, D.C., October 10, 2002.
 Developmental Disabilities Nursing Association, Hillside, IL, November 6, 2002.
 LaRabida Children's Hospital (University of Chicago), Grand Rounds, Chicago,
 IL, November 8, 2002.
 Illinois Health Care Association, Bloomingdale, IL, November 10, 2002.
 Department of Neurology, Lurie Children's Hospital, Chicago, IL,
 November 20, 2012.

Invited lecturer, "Persistent Vegetative State and Minimally Conscious State":
 International Conference on Life Care Planning, Atlanta, Georgia,
 October 15, 2006.

Neurology Grand Rounds, Mayo Clinic, Rochester, MN, April 8, 2013, followed by two days
 of ward rounds and seminars with medical students, neurology residents in training,
 and Mayo Clinic staff members.

ORGANIZED WORKSHOPS:

The most time-consuming workshop activity has been organizing the pediatric long-term care workshop sessions that have taken place during the annual American Medical Director Association symposia. I had to work to attract enough presenters, and attendees, starting with 1998, through 2005, to fully fill the available three days of pediatric long term care sessions (this has been a total of 8 years of hard work and dedication).

Below is a listing of the workshops that I personally conducted:

"Live Expectancy of Children with Severe Neurologic Handicaps" (Medical Direction Workshop), American Medical Directors Association Annual Symposium, February 15, 1997, Phoenix, Arizona.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, February 16, 1997, Phoenix, Arizona.

“Medical Direction: Pediatric Skilled Nursing Facilities” (Medical Direction Workshop), American Medical Directors Association Annual Symposium, March 6, 1998, San Antonio, Texas.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 7, 1998, San Antonio, Texas.

“Pediatric Long Term Care: Management of Spasticity” (Medical Direction Workshop), American Medical Directors Association Annual Symposium, March 5, 1999, Orlando, Florida.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 6, 1999, Orlando, Florida.

“Overview of Long-Term Care” (Core Curriculum of Medical Direction), American Medical Directors Module A, May 15, 1999, Cleveland, Ohio.

“Infection Control” (Core Curriculum of Medical Direction), American Medical Directors Module A, May 16, 1999, Cleveland, Ohio.

“Infection Control in Pediatric Facilities” (Medical Direction Workshop), American Medical Directors Association Annual Symposium, March 17, 2000, San Francisco, California.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 18, 2000, San Francisco, California.

“Recent Clinical Advances in Pediatric Long-Term Care” (Medical Direction Workshop), American Medical Directors Association Annual Symposium, March 16, 2001, Atlanta, Georgia.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 17, 2001, Atlanta, Georgia.

“Clinical Research in Pediatric Long-Term Care: Practical and Ethical Issues,” American Medical Directors Association Annual Symposium, March 21, 2002, San Diego, CA.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 22, 2002, San Diego, CA.

“Cost Reduction of Pulmonary Disease in Neuromuscularly Impaired Pediatric Patients,” American Medical Directors Association Annual Symposium, March 7, 2003, Orlando, FL.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 8, 2003, Orlando, FL.

“An Update on Survival Rates of Disabled Children,” American Medical Directors Association Annual Symposium, March 4, 2004, Phoenix, AZ.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 5, 2004, Phoenix, AZ.

“Pediatric Best Care Practices: Pediatric Progress and Plans,” American Medical Directors Association Annual Symposium, March 17, 2005, New Orleans, LA.

“Advanced Directives and Do Not Resuscitate Orders in Pediatric Long Term Care,” American Medical Directors Association Annual Symposium, March 17, 2005, New Orleans, LA.

“In The Trenches: Pediatric Long-Term Care Roundtable,” American Medical Directors Association Annual Symposium, March 19, 2005, New Orleans, LA.

“Persistent Vegetative State and Minimally Conscious State,” American Medical Directors Association Annual Symposium, March 17, 2006, Dallas, TX.

PEER-REVIEWED ARTICLES AND BOOK CHAPTERS:

1. Murray, J., Plioplys, A.V.: An Indicator-dilution technique for study of blood-to-brain solute passage in the rat. Journal of Applied Physiology. 33:681-3, 1972.
2. Plioplys, A.V., Kleinberg, F., Okazaki, H. Weight loss as a factor in the development of kernicterus. Minnesota Medicine. 1983.
3. Kleinberg, F., Plioplys, A.V.: Hyperbilirubinemia and the low-birth weight infant, in Mellinger, J.F., Stickler, G.B., (eds): Critical Problems in Pediatrics, Philadelphia, J.B. Lippincott, pp 24-34, 1983.
4. Plioplys, A.V., Childs, C.L., Rosenfeld, R.G., Stickler, G.B. Growth factors and fibroblast growth factor receptors in cerebral gigantism, in Berg, J.M. (ed): Perspectives and Progress in Mental Retardation: Volume II - Biomedical Aspects, Baltimore, MD., University Park Press, pp. 257-264, 1984.
5. Plioplys, A.V., Thibault, J., Hawkes, R. Selective staining of a subset of Purkinje cells in the human cerebellum with monoclonal antibody MabQ113. Journal of the Neurological Sciences. 70:245-256, 1985.
6. Plioplys, A.V. Weight loss and the development of kernicterus (Svorio paradimas ir smegenine gelta kudikiuose). Medicina (Chicago). 66:3-6, 1985.
7. Leclerc, N., Gravel, C., Plioplys, A.V., Hawkes, R.: Basket cell development in the normal and hypothyroid rat cerebellar cortex studied with a monoclonal anti-neurofilament antibody. Canadian Journal of Biochemistry and Cell Biology. 63:564-576, 1985.

8. Plioplys, A.V. Cerebral gigantism. American Journal of Diseases of Children. 140:9, 1986.
9. Plioplys, A.V., Hawkes, R.B. A survey of MabQ113 immunoreactivity in the adult rat brain: differential staining of the lateral and medial habenular nuclei. Brain Research. 375:1-12, 1986.
10. Plioplys, A.V., Gravel, C., Hawkes, R.B. Selective suppression of neurofilament antigen expression in the hypothyroid rat cerebral cortex. Journal of the Neurological Sciences. 75:53-68, 1986.
11. Gravel, C., Leclerc, N., Plioplys, A.V., Hawkes, R.: Focal axonal swellings in rat cerebellar Purkinje cells during normal development. Brain Research. 363:325-332, 1986.
12. Plioplys, A.V., Hawkes, R.B. Differential immunoreactivity in the rat habenular complex during postnatal development. Brain Research Bulletin. 18:19-24, 1987.
13. Plioplys, A.V., Thibault, J., Bouchard, J.P., Cockburn, C., Hawkes, R.B. Anti-CNS antibodies in neurologic and psychiatric disorders. Journal of Neurology, Neurosurgery and Psychiatry. 50:1514-1521, 1987.
14. Plioplys, A.V. Down's Syndrome: precocious neurofilament antigen expression. Journal of the Neurological Sciences. 79:91-100, 1987.
15. Plioplys, A.V. Down's syndrome: cytoskeletal abnormalities. Down's Syndrome Papers and Abstracts. 10:1-3, 1987.
16. Plioplys, A.V. Monoclonal antibodies and the central nervous system (Monoklonalniia prieskuniai ir nervu sistema). Medicina (Chicago). 69:8-10, 1987.
17. Plioplys, A.V. Expression of the 210Kdalton neurofilament subunit in cultured central nervous system from normal and trisomy 16 mice: regulation by interferon. Journal of the Neurological Sciences. 85:209-222, 1988.
18. Plioplys, A.V., Hawkes, R. The expression of monoclonal antibody Q113 immunoreactivity in the rat cerebral cortex: unique differential sublayering of layer I; staining of radial glia. Journal of Neuroscience Research. 20:359-375, 1988.
19. Plioplys, A.V., Bedford, H.M. Murine trisomy 16 model of Down's syndrome: central nervous system electron microscopic observations. Brain Research Bulletin. 22:233-243, 1989.
20. Plioplys, A.V., Greaves, A., Yoshida, W. Anti-CNS antibodies in childhood neurologic diseases. Neuropediatrics. 20:93-102, 1989.

21. Plioplys, A.V. Autism: biomedical perspectives. Proceedings of the Autism Society of America. 2-7, 1989.
22. Plioplys, A.V. Autism: immunologic investigations, in Gillberg, C. (ed): Diagnosis and Treatment of Autism, New York, Plenum Press, pp. 133-138, 1989.
23. Plioplys, A.V., Hemmens, S.E., Regan, C.M. Expression of a NCAM serum fragment is depressed in autism. Journal of Neuropsychiatry. 2:413-417, 1990.
24. Plioplys, A.V. Trisomy 16 mouse model of Alzheimer's Disease, in Iqbal, K. (ed): Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. Wiley, London, pp. 479-485, 1990.
25. Gorelick, P.B., Hier, D.B., Mangone, C., Robbins, S., Plioplys, A.V., Kathpalia, S.: Status of aluminum as a risk factor for dialysis encephalopathy and Alzheimer's disease (editorial). International Journal of Artificial Organs. 14:70-73, 1991.
26. Plioplys, A.V., Kasnicka, I. L-carnitine as a treatment for Rett syndrome. Southern Medical Journal. 86:1411-1413, 1993.
27. Jason, L.A., Fitzgibbon, G., Taylor, R., Taylor, S., Wagner, L., Johnson S., Richmond, G.W., Papernik, M., Plioplys, A.V., Plioplys, S., Lipkin, D., Ferrari, J. The prevalence of Chronic Fatigue Syndrome: a review of efforts--past and present. CFIDS Chronicle, Summer, 1993: 24-29.
28. Plioplys, S., Plioplys, A.V. Chronic Fatigue Syndrome (Letinis Nuovargio Sindromas). Medicina (Chicago). 82:15-17, 1993.
29. Plioplys, A.V., Greaves, A., Kazemi, K., Silverman, E. Lymphocyte function in autism and Rett syndrome. Neuropsychobiology. 29:12-16, 1994.
30. Plioplys, A.V. Autism: EEG abnormalities and clinical improvement with valproic acid. Archives of Pediatrics and Adolescent Medicine. 148:220-222, 1994.
31. Plioplys, A.V., Greaves, A., Kazemi, K., Silverman, E. Immunoglobulin reactivity in autism and Rett syndrome. Developmental Brain Dysfunction. 7:12-16, 1994.
32. Plioplys, A.V., Bagherpour, S., Kasnicka, I. L-carnitine as a treatment of lethargy in children with chronic neurologic handicaps. Brain and Development. 16:146-149, 1994.
33. Plioplys, A.V. Selective suppression of maternal IgG anti-central nervous system antibody reactivity. Developmental Brain Dysfunction. 7:165-170, 1994.
34. Plioplys, A.V., Massimini, N. Alpha/beta interferon is a neuronal growth factor. Neuroimmunomodulation. 2:31-35, 1995.

35. Plioplys, A.V., Plioplys, S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology. 32:132-138, 1995.
36. Plioplys, A.V. Deficiency of a neuronal growth-sustaining factor in fibroblasts of patients with Alzheimer's Disease. Journal of the Neurological Sciences. 133:24-30, 1995.
37. Plioplys, A.V., Plioplys, S. Electron microscopic investigation of muscle mitochondria in Chronic Fatigue Syndrome. Neuropsychobiology. 32:175-181, 1995.
38. Plioplys, S., Plioplys, A.V. Chronic Fatigue Syndrome (Myalgic Encephalopathy): a review. Chicago Medicine. 98:11-15, 1995.
39. Plioplys, S., Plioplys, A.V. Chronic Fatigue Syndrome (Letinis Nuovargio Sindromas). Medicina (Chicago). 85:10-11, 1995.
40. Plioplys, S., Plioplys, A.V. Chronic Fatigue Syndrome (Myalgic Encephalopathy): a review. Southern Medical Journal. 88:993-1000, 1995.
41. Jason, L.A., Taylor, R., Wagner, L., Holden, J., Ferrari, J.R., Plioplys, A.V., Plioplys, S., Lipkin, D., Papernik, M. Estimating rates of Chronic Fatigue Syndrome from a community based sample: a pilot study. American Journal of Community Psychology. 23:557-568, 1995.
42. Lipkin, D.M., Robin, R., Vasquez, L., Plioplys, A.V., Plioplys, S.: Chronic fatigue syndrome. Journal of Neurology, Neurosurgery and Psychiatry. 58:764-765, 1995.
43. Plioplys, A.V., Plioplys, S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology. 35:16-23, 1997.
44. Plioplys, A.V. Anti-muscle and anti-CNS circulating antibodies in Chronic Fatigue Syndrome. Neurology. 48:1717-1719, 1997.
45. Plioplys, A.V., Plioplys, S. Meeting the frustrations of Chronic Fatigue Syndrome. Hospital Practice. 32:147-166, 1997.
46. Plioplys, A.V. Chronic Fatigue Syndrome should not be diagnosed in children. Pediatrics. 100:270-271, 1997.
47. Jason, L.A., Ropacki, M.T., Santoro, N.B., Richman, J.A., Heatherly, W., Taylor, R., Ferrari, J.R., Haney-Davis, T.M., Rademaker, A., Dupuis, J., Golding, J., Plioplys, A.V., Plioplys, S. A screening instrument for Chronic Fatigue Syndrome: Reliability and validity. Journal of Chronic Fatigue Syndrome. 3:39-59, 1997.
48. Plioplys, A.V., Kasnicka, I., Lewis, S., Moller, D. Survival rates of children with severe neurologic disabilities. Southern Medical Journal. 91:161-170, 1998.

49. Plioplys, A.V. Intravenous immunoglobulin treatment of children with autism. Journal of Child Neurology. 13:79-82, 1998.
50. Jason, L.A., Wagner, L., Rosenthal, S., Goodlatte, J., Lipkin, D., Papernik M., Plioplys, S., Plioplys, A.V. Estimating the prevalence of Chronic Fatigue Syndrome among nurses. American Journal of Medicine. 105:91S-93S, 1998.
51. Jason, L.A., Richman, J.A., Rademaker, A.W., Jordan, K.M., Plioplys, A.V., Taylor, R.R., McCready, W., Huang, C.F., Plioplys, S. A community-based study of Chronic Fatigue Syndrome. Archives of Internal Medicine. 159: 2129-2137, 1999.
52. Plioplys, A.V. Treatment of autistic children with intravenous immunoglobulin. Journal of Child Neurology. 14: 203-205, 1999.
53. Plioplys, A.V. Different rates of Chronic Fatigue Syndrome amongst high school students in two British Boroughs. Journal of Chronic Fatigue Syndrome. 5: 97-98, 1999.
54. Plioplys, A.V. Intravenous immunoglobulin treatment in autism. Journal of Autism and Developmental Disorders. 30:73-74, 2000.
55. Plioplys, A.V. Medical assessment of Chronic Fatigue Syndrome. Neurologijos Seminarai (Lithuania), 3:68-76, 2001.
56. Plioplys, A.V. Sydenham's chorea and PANDAS. Neurologijos Seminarai (Lithuania), 3:21-24, 2001.
57. Plioplys, A.V. An ethical response to Peter Singer. Caring for the Ages. 2:11-13, 2001.
58. Plioplys, A.V., Lewis, S., Kasnicka, I. Pulmonary vest therapy in pediatric long-term care. Journal of the American Medical Directors Association, 3:318-321, 2002.
59. Plioplys, A.V. Differential diagnosis in medical assessment. Book chapter, in Handbook of Chronic Fatigue Syndrome, ed. L. A. Jason, P. A. Fennell, R. R. Taylor, John Wiley & Sons, Inc. NY, pages 26-41, 2003.
60. Plioplys, A.V. Survival Rates of Children with Severe Neurologic Disabilities: a Review. Seminars in Pediatric Neurology, 10: 120-129, 2003.
61. Jason, L.A., Plioplys, A.V., Torres-Harding, S., Corradi, K. Comparing symptoms of Chronic Fatigue Syndrome in a community-based versus tertiary care sample. Journal of Health Psychology, 8: 459-464, 2003.
62. Plioplys, A.V. Pediatric Skilled Nursing Facilities: Improved Survival Rates. Vulnerable Populations in the Long Term Care Continuum, (eds. Katz, P.R., Mezey, M.D., Kapp, M.B.) Springer, pages 109-131, 2004.

63. Plioplys, A.V. Life Expectancy of Severely Disabled Children: a Brief Review. Pediatric Life Care Planning and Case Management, (ed. Riddick-Grisham, S.) CRC Press, pages 781-795, 2004.
64. Plioplys, A.V. Vaiku su Sunkiū Cerebriniu Paralyziumi Isgyvenamumas: Trumpa Alzvalga (Life Expectancy of Severely Disabled Children: a Brief Review). Neurologijos Seminarai (Lithuania) 2: 10-19, 2004.
65. Plioplys, A.V. Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular disease: an exploratory randomized controlled trial. Journal of Child Neurology, 25:1598, 2010.
66. Plioplys, A.V. Fusion of Neuroscience and Art, Lancet (Neurology), 9:350-351, 2010.
67. Plioplys A.V. Nebulized tobramycin: Prevention of pneumonias in patients with severe cerebral palsy. Journal of Pediatric Rehabilitation Medicine, 4:155-158, 2011.
68. Plioplys, A.V. Life expectancy determinations: cerebral palsy, traumatic brain disorder, and spinal cord; analysis and comparison. Journal of Life Care Planning, 11:25-38, 2012.
69. Kubasiak, L., Pandya J., Plioplys, A.V. An aquatic physical therapy program for adults with severe-profound developmental disabilities. Journal of Aquatic Physical Therapy, 24:41-49, 2016.

PEER-REVIEWED PUBLISHED ABSTRACTS:

1. Plioplys, A.V., Kleinberg, F., Okazaki, H. Weight loss--a factor in the development of kernicterus. Proceedings of the Northwestern Pediatric Society, Minneapolis, Minnesota, September 25, 1981.
2. Plioplys, A.V., Kleinberg, F. Birth weight and the incidence of kernicterus: unreliability of per-exchange bilirubin levels. Proceedings of the Midwest Society for Pediatric Research, Detroit, Michigan, November 3, 1981.
3. Plioplys, A.V. Kernicterus. Proceedings of the Fourth Lithuanian Symposium on Arts and Sciences, Chicago, Illinois, November 26, 1981.
4. Plioplys, A.V., Ryer, D.E., Roskos, R.R., Go, V.L.W., Yaksh, T.L. CSF Substance P, VIP and CCK - laboratory and clinical correlates. Neurology. 32:A107-8, 1982.
5. Plioplys, A.V., CSF CCK, VIP and Substance P in mental retardation syndromes and in children undergoing cranial irradiation and intrathecal chemotherapy. International Association for the Scientific Study of Mental Deficiency, Toronto, Ontario, Canada, 1982.

6. Plioplys, A.V. Growth factors and fibroblast growth factor receptors in cerebral gigantism (abstract). International Association for the Scientific Study of Mental Deficiency, Toronto, Ontario, Canada, 1982.
7. Plioplys, A.V., CSF pressure and CT scan findings in cerebral gigantism (abstract). International Association for the Scientific Study of Mental Deficiency, Toronto, Ontario, Canada, 1982.
8. Plioplys, A.V., Thibault, J., Hawkes, R. Le marquage selectif d'un ensemble de cellules de Purkinje dans le cervelet humain avec un anticorps monoclonal MabQ113. Proceedings of the 53rd Congress of the Association Canadienne--Francaise Pour l'Avancement des Sciences, Chicoutimi, Quebec, 52-53:227, 1985.
9. Plioplys, A.V., Hawkes, R. Synaptogenesis in the mouse cerebral cortex studied with monoclonal antibody MabQ155. Canadian Journal of Neurological Sciences. 12:216, 1985.
10. Plioplys, A.V., Thibault, J., Hawkes, R. Selective staining of a subset of Purkinje cells in the human cerebellum with monoclonal antibody MabQ113. Canadian Journal of Neurological Sciences. 12:216, 1985.
11. Leclerc, N., Gravel, G., Plioplys, A.V., Hawkes, R. Parasagittal bands in rat cerebellar cortex produced by selective repression of antigen expression. Canadian Journal of Neurological Sciences. 12:218-9, 1985.
12. Gravel, C., Leclerc, N., Plioplys, A.V., Hawkes, R. Focal axonal swellings in rat cerebellar Purkinje cells during normal development. Canadian Journal of Neurological Sciences. 12:194, 1985.
13. Gravel, C., Leclerc, N., Plioplys, A.V., Hawkes, R. Axonal development in normal and hypothyroid rat cerebellar cortex. Neuroscience Abstracts. 11:898, 1985.
14. Plioplys, A.V. Monoclonal antibodies and the nervous system. Proceedings of the Fifth Lithuanian Symposium on Science and Creativity, Chicago, IL, November 29, 1985.
15. Thibault, M., Plioplys, A.V., Fortin, G., Verret, S., Bouchard, J.P. Kinsbroune's ataxia-opsoclonus-myoclonus syndrome: clinical and immunologic investigations. Canadian Journal of Neurological Sciences. 13:167, 1986.
16. Plioplys, A.V., Thibault, J., Bouchard, J.P., Cockburn, C., Hawkes, R. Serum anti-brain antibodies in neurologic and psychiatric disorders and in normal controls. Canadian Journal of Neurological Sciences. 13:182, 1986.
17. Plioplys, A.V., Gravel, C., Hawkes, R.B. Neurofilament antigen expression in the rat cerebral cortex: differential sensitivity to hypothyroidism. Canadian Journal of Neurological Sciences. 13:199, 1986.

18. Plioplys, A.V., Hawkes, R.B. Expression of monoclonal antibody Q113 immunoreactivity in the rat cerebral cortex: two classes of astrocytes; unique differential sublayering of layer I; staining of radial glia. Neuroscience Abstracts. 12(1):350, 1986.
19. Plioplys, A.V. Monoclonal antibody SV16 recognizes synaptic vesicles in human CNS tissue. Southern Ontario Neuroscience Association, Toronto, Canada, May 8, 1987.
20. Plioplys, A.V., Percy, M.E., Dalton, A.J., McLachlan, D.R. Anti-CNS antibody activity in Down's syndrome. Journal of Neuroimmunology. 16:139-140, 1987.
21. MacFabe, D., Lew, J., Scott, B., Plioplys, A.V. Interferon induces differential redistribution of the 210Kdalton neurofilament subunit in cultured dorsal root ganglia cell bodies from normal and trisomy 16 mice. Neuroscience Abstracts. 13(2):1138, 1987.
22. Plioplys, A.V. Expression of the 210Kdalton neurofilament subunit in cultured central nervous system from normal and trisomy 16 mice: regulation by interferon. Proceedings 8th European Conference on Brain Research, France, March 1988, p.99.
23. Plioplys, A.V., Bedford H.M. Murine trisomy 16 model of Down's Syndrome: central nervous system electron microscopic observations. Proceedings 8th European Conference on Brain Research, France, March 1988, p.78.
24. Plioplys, A.V. Expression of the 210Kdalton neurofilament subunit in cultured central nervous system from normal and trisomy 16 mice: regulation by interferon. Annals of Neurology. 24:312-3, 1988.
25. Plioplys, A.V., Bedford, M. Murine trisomy 16 model of Down's syndrome: central nervous system electron microscopic observations. Annals of Neurology. 24:305, 1988.
26. Plioplys, A.V., Greaves A., Yoshida W. Anti-CNS antibodies in childhood neurologic diseases. Annals of Neurology. 24:331, 1988.
27. Hoshino, C., Greaves, A., Yoshida, W., Silverman, E., Plioplys, A.V. Demonstration of anti-CNS antibodies in sera of systemic lupus erythematosus (SLE) patients by western blots and immunohistochemistry using human CNS tissue. Annals of Neurology. 24:330, 1988.
28. Plioplys, A.V. Trisomy 16 mouse model of Down syndrome: 210Kdalton neurofilament subunit regulation by interferon; central nervous system electron microscopic observations. Neuroscience Abstracts. 14(2):1201, 1988.
29. Plioplys, A.V. Murine trisomy 16 model of Down's Syndrome and Alzheimer's disease: cytoskeletal expression in CNS tissue sections. Neurology. 39 (1): 191, 1989.

30. Plioplys, A.V. Murine trisomy 16 model of Down's Syndrome and Alzheimer's disease: cytoskeletal expression in CNS tissue cultures. Neurology. 39(1):250, 1989.
31. Plioplys, A.V., Greaves, A., Kazemi, K., Silverman, E. Autism: anti-210K neurofilament immunoglobulin reactivity. Neurology. 39(1):187, 1989.
32. Plioplys, A.V.: Mother-infant anti-CNS antibody reactivity. Canadian Journal of Neurological Sciences. 16:242-243, 1989.
33. Plioplys, A.V., Greaves, A., Kazemi, K., Silverman, E. Lymphocyte function in autism. Canadian Journal of Neurological Sciences. 16:245-246, 1989.
34. Plioplys, A.V., Hemmens, S.E., Regan, C.M. Expression of a NCAM serum fragment is depressed in autism. Annals of Neurology. 26:483, 1989.
35. Plioplys, A.V. Autism: biomedical assessment and interventions. Proceedings of the Southern Medical Association. Washington, DC. November, 1989.
36. Plioplys, A.V. Autism: immunologic investigations. Proceedings of the Southern Medical Association. Washington, DC. November, 1989.
37. Plioplys, A.V. Expression of a NCAM serum fragment is depressed in autism. Proceedings of the Southern Medical Association. Washington, DC. November, 1989.
38. Plioplys, A.V., Greaves, A. Immune system investigations in Rett syndrome. Neurology. 40(1):361, 1990.
39. Plioplys, A.V. Trisomy 16 mouse model of Alzheimer's Disease. Neurobiology of Aging. 11:326, 1990.
40. Plioplys, A.V., Massimini, N. Alpha and beta interferon are neuronal growth factors. Neurology. 42(3):185, 1992.
41. Plioplys, A.V., Plioplys, S. Amantadine therapy of Chronic Fatigue Syndrome. Annals of Neurology. 36:303, 1994.
42. Jason, L.A., Taylor, R., Wagner, L., Holden, J., Ferrari, J.R., Plioplys, A.V., Plioplys, S., Lipkin, D., Papernik, M. A pilot study estimating rates of Chronic Fatigue Syndrome from a community based sample. Proceedings of the American Association for Chronic Fatigue Syndrome. October, p. 10, 1994.
43. Plioplys, S., Plioplys, A.V. Serum levels of carnitine in Chronic Fatigue Syndrome: clinical correlates. Proceedings of the American Association for Chronic Fatigue Syndrome. October, p. 19, 1994.
44. Plioplys, S., Plioplys, A.V. Amantadine and L-carnitine therapy of Chronic Fatigue Syndrome: preliminary results. Proceedings of the American Association for Chronic

Fatigue Syndrome. October, p. 92, 1994.

45. Plioplys, A.V., Plioplys, S. Electron microscopic investigation of muscle mitochondria in Chronic Fatigue Syndrome. Neuroscience Abstracts. 21:1490, 1995.
46. Plioplys, A.V. Abnormal EEG in autism: valproate response. Progress in Pediatric Neurology (ed. J. Gordon Millichap), PNB Publishers, Chicago, Illinois, pages 126 and 239, 1997.
47. Plioplys, A.V. Clinical research in pediatric long term care. Proceedings of the American Medical Directors Association, Phoenix, Arizona, February 13-16, 1997.
48. Plioplys, A.V., Kasnicka, I., Lewis, S., Moller, D. Survival Rates of Children with Severe Neurologic Disabilities. Child Neurology Society, Phoenix, Arizona, October 31, 1997. Annals of Neurology. 42:501, 1997.
49. Plioplys, A.V., Kasnicka, I., Lewis, S., Moller, D. Survival rates of G-tube fed children: relation to fundoplication. Proceedings of the American Medical Directors Association, San Antonio, Texas, March, 1998.
50. Plioplys, A.V., Kasnicka, I., Lewis, S., Moller, D. Survival Rates of Children with Severe Neurologic Disabilities. International Child Neurology Society Meeting, Ljubliana, Slovenia. September 13-17, 1998. Brain and Development. 20:440, 1998.
51. Plioplys, A.V., Kasnicka, I., Lewis, S., Moller, D. Survival rates of G-tube fed children: relation to fundoplication. International Child Neurology Society Meeting, Ljubliana, Slovenia. September 13-17, 1998. Brain and Development. 20:440, 1998.
52. Plioplys, A.V., Kasnicka, I., Murphy, P. Calcitonin treatment of osteoporosis in pediatric long-term care. Presentation at the annual meeting of the American Medical Directors Association, March, 2000, San Francisco, California; Journal of the American Medical Directors Association. 1:A7, 2000. (This paper won second place amongst 76 medical research presentations.)
53. Plioplys, A.V., Kasnicka, I., Fowler, L., Murphy, P. Osteoporosis in pediatric long-term care. Presentation at the annual meeting of the American Medical Directors Association, March, 2000, San Francisco, California; Journal of the American Medical Directors Association. 1:A7, 2000.
54. Plioplys, A.V., Kasnicka, I., Lewis, S. Ketogenic diet as a treatment of refractory epilepsy in the pediatric skilled nursing facility. Presentation at the annual meeting of the American Medical Directors Association, March, 2000, San Francisco, California; Journal of the American Medical Directors Association. 1:A7, 2000.
55. Plioplys, A.V., Kasnicka, I., Fowler, L., Lewis, S., Murphy, P. Osteoporosis in Severe Cerebral Palsy. Presentation at the annual meeting of the Child Neurology Society, October, 2000, St. Louis, Missouri; Annals of Neurology. 48: 545, 2000.

56. Plioplys, A.V., Kasnicka, I., Murphy, P. Calcitonin Treatment of Osteoporosis in Severe Cerebral Palsy. Presentation at the annual meeting of the Child Neurology Society, October, 2000, St. Louis, Missouri; Annals of Neurology. 48: 545, 2000.
57. Plioplys, A.V., Kasnicka, I., Torres, L., Lewis, S., Murphy, P. Osteoporosis in pediatric long-term care: II. Presentation at the annual meeting of the American Medical Directors Association, March, 2001, Atlanta, Georgia; Journal of the American Medical Directors Association, 2:A16, 2001.
58. Plioplys, A.V., Kasnicka, I. Calcitonin treatment of osteoporosis in pediatric long-term care: II. Presentation at the annual meeting of the American Medical Directors Association, March, 2001, Atlanta, Georgia; Journal of the American Medical Directors Association, 2:A16, 2001.
59. Plioplys, A.V., Lewis, S. Pulmonary vest therapy in pediatric long-term care: Presentation at the annual meeting of the American Medical Directors Association, March, 2001, Atlanta, Georgia; Journal of the American Medical Directors Association, 2:A17, 2001.
60. Plioplys, A.V., Kasnicka, I., Lewis, S. Calcitonin treatment of osteoporosis in pediatric long-term care: III. Presentation at the annual meeting of the American Medical Directors Association, March, 2002, San Diego, California. Journal of the American Medical Directors Association, 3:A17, 2002.
61. Plioplys, A.V., Lewis, S., Kasnicka, I. Pulmonary vest therapy in pediatric long-term care: II. Presentation at the annual meeting of the American Medical Directors Association, March, 2002, San Diego, California. Journal of the American Medical Directors Association, 3:A18, 2002.
62. Plioplys, A.V. Survival rates of children with severe neurologic disabilities in pediatric skilled nursing facilities. Presentation at the annual meeting of the American Medical Directors Association, March, 2002, San Diego, California. Journal of the American Medical Directors Association, 3:A18, 2002.
63. Plioplys, A.V., Kasnicka, I., Lewis, S. Osteoporosis in quadriplegic cerebral palsy: risk factors, protective effect of epilepsy and anticonvulsants. Presentation at the annual meeting of the Child Neurology Society, October, 2002, Washington, DC. Annals of Neurology, 52:S145-146, 2002.
64. Plioplys, A.V., Kasnicka, I., Lewis, S. Calcitonin treatment of osteoporosis in quadriplegic cerebral palsy. Presentation at the annual meeting of the Child Neurology Society, October, 2002, Washington, DC. Annals of Neurology, 52:S156, 2002.
65. Plioplys, A.V., Kasnicka, I., Lewis, S. Pulmonary vest therapy in quadriplegic cerebral palsy. Presentation at the annual meeting of the Child Neurology Society, October, 2002, Washington, DC. Annals of Neurology, 52:S156, 2002.

66. Plioplys, A.V., Kasnicka, I., Lewis S. Calcitonin treatment of osteoporosis in quadriplegic cerebral palsy. Presentation at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine, September 2003, Montreal, Quebec, Canada. Developmental Medicine and Child Neurology, 45 (suppl. 96): 32, 2003.
67. Plioplys, A.V., Kasnicka, I., Lewis S. Osteoporosis in quadriplegic cerebral palsy: risk factors, protective effect of epilepsy and anticonvulsants. Presentation at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine, September 2003, Montreal, Quebec, Canada. Developmental Medicine and Child Neurology, 45 (suppl. 96): 33, 2003.
68. Plioplys, A.V., Ebel, J., Kasnicka, I. Pulmonary vest therapy to prevent pneumonias in quadriplegic cerebral palsy. Presentation at the annual meeting of the American Congress of Rehabilitation Medicine and the American Society for Neurorehabilitation, October 2003, Tucson, AZ. Archives of Physical Medicine and Rehabilitation, 84: A6-A8, 2003.
69. Plioplys, A.V., Ebel, J., Kasnicka, I. Cost savings of pulmonary vest therapy. Presentation at the annual meeting of the American Congress of Rehabilitation Medicine and the American Society for Neurorehabilitation, October 2003, Tucson, AZ. Archives of Physical Medicine and Rehabilitation, 84: A6-A8, 2003.
70. Plioplys, A.V., Peterman, P. Effect of government regulations on death rates of severely disabled, cerebral palsied children. Presentation at the annual meeting of the Child Neurology Society, October 2004, Ottawa, Ontario, Canada. Annals of Neurology, 56: (suppl. 8): S125, 2004.
71. Plioplys, A.V., Peterman, P. Effect of government regulations on death rates of severely disabled, cerebral palsied children. Presentation at the annual meeting of the American Medical Directors Association, March 2005, New Orleans, Louisiana, Journal of the American Medical Directors Association, 6: B15, 2005.

WEB ARTICLES (available at www.plioplys.com):

In the section "Survival Rates / Life Expectancy Articles":

Response to David Strauss, May 9, 2004.

1998 Survival Rates are an Underestimate, October, 2004.

Comparison Eyman vs. Plioplys, October, 2004.

Response to David Strauss and Dr. Richard Katz, November 14, 2005.

Factors That Improve the Life Expectancy of the Severely Disabled,
October 8, 2007.

Response to Richard Katz MD, March 9, 2011.

In the section “Other Pediatric Long Term Care Articles”:

Persistent Vegetative State / Minimally Conscious State, October, 2006
Pediatric Nursing Facility Protocols

In the section “Other Pediatric Neurology Articles”:

Redefinition of Hypoxic Ischemic Encephalopathy, February, 2007
European Definition of Perinatal Asphyxial Encephalopathy, October, 2009

CITATIONS:

Citations of my published work have appeared in:

New England Journal of Medicine,
Proceedings of the National Academy of Sciences,
New York Times,
 Innumerable clinical and research medical publications.

Of note are citations of my clinical research results in Pediatric Neurology: Principles and Practice, fifth edition, 2012, edited by Drs. Kenneth F. Swaiman, Stephen Ashwal, Donna M. Ferrero, and Nina F. Schor. This is an encyclopedic, two volume textbook, 1,982 pages in length, and considered by most child neurologists to be the "Bible" of child neurology.

In Chapter 43, “Global Developmental Delay and Mental Retardation / Intellectual Disability,” written by Drs. Elliott T. Sherr and Michael I. Shevell, one of my survival rate studies is cited on page 574 (this resume article #45). Of note is that there were only three other references cited concerning survival rates of disabled children.

In Chapter 48, “Autistic Spectrum Disorders,” written by Drs. Deborah G. Hirtz, Ann Wagner and Pauline A. Filipek, my study concerning the use of intravenous immunoglobulin to treat autistic children is cited on page 659 (this resume article #46).

In Chapter 55, “Epileptiform Disorders with Cognitive Symptoms,” written by Dr. Roberto Tuchman, my study concerning the use of anticonvulsants to treat autistic children with epileptiform disturbances on electroencephalograms is cited (this resume article #28).

In Chapter 69, “Cerebral Palsy,” written by Drs. Kenneth F. Swaiman and Yvonne Wu, my survival rate studies are cited on page 1,000 (this resume articles #45 and #53). Of note is that out of six cited articles, about survival rates of CP children, two were written by myself.

ARTICLES ABOUT THE NEUROSCIENCE/NEUROLOGY WORK OF DR. PLIOPLYS

Fourth Lithuanian Symposium on Arts and Sciences, Chicago, IL, November 25-29, 1981.

Lithuanian Encyclopedia, volume 37, Boston, MA, p. 466, 1985.

Fifth Lithuanian Symposium on Arts and Sciences, Chicago, IL, November 27-December 1, 1985.

Arnold Rincover, "Does brain protein kill Alzheimer's patients?" The Toronto Star, Toronto, Canada, July 25, 1987.

Marvin Ross, "How Down's damages the fetus", The Globe and Mail, Toronto, Canada, August 15, 1987.

Marvin Ross, "Physiological links to autism increase", The Globe and Mail, Toronto, Canada, March 18, 1989.

Game Plan: Research at Michael Reese, 1990.

Theodore Berland, "Secret to Alzheimer's disease lies deep inside cells", Michael Reese News, June 1990.

Theodore Berland, "Researchers share advances against Alzheimer's"; and James Bolger "MRIC allocates research funds", Michael Reese News, July/August 1990.

Ray Long, "Man in coma needs miracle for recovery, court is told." Chicago Sun-Times, p. 14, September 28, 1990.

"Mercy offers families hope", Life Times, spring 1991.

"Mercy opens Alzheimer's Disease Center", Life Times, winter 1991.

"Helping families cope with Alzheimer's", Momentum, Mercy Eldercare, fall 1992.

"Mercy Neurologist: Finding new way to treat autism", Reflections, December 1992.

"Physician profile", Reflections, January 1993.

"Physician news", Reflections, April 1993.

"CFS Clinic and Research Center opens at local hospital", CFSSI Circular, Summer 1993.

Ruth Robin, "CFS Treatment and Evaluation Center: the full picture", CFSSI Circular, fall, 1993.

"Amantadine and L-carnitine for chronic fatigue", Neurology Reviews, September/October,

1993.

"Mercy's Alzheimer's Center: offering patients the latest medications", Reflections, November, 1993.

"Your association awards \$25,000 for CFS research", Chronic Fatigue Syndrome Association of Minnesota, fall, 1993.

Sydney S. Gellis, "Treatment of Rett Syndrome with L-carnitine", Pediatric Notes, January 6, 1994.

"CFS treatment study", CFSSI Circular, Winter, 1993/94.

Bernard Rimland, "More clues point to immune disorder", and "Seizure drugs: not just for seizures?", Autism Research Review International, spring, 1994.

Proclamation by Jim Edgar, Governor of the State of Illinois, February 14, 1994, recognizing the CFS Evaluation and Treatment Center, established by Dr. Plioplys.

"Finding information and support programs", The Star, June 23, 1994.

"Mitochondrial abnormalities in chronic fatigue", Neurology Reviews, May/June, 1994.

Ruth Robins, "More Grand Rounds", "More television coverage", and "Muscle mitochondrial abnormalities in CFS: an electron microscopic investigation", CFSSI Circular, Summer, 1994.

"Chronic Fatigue Syndrome: an elusive, debilitating ailment", Reflections, July 1994.

"Physician news", Reflections, September/October 1994.

Chicago Tribune, March 2, 1995.

"Muscle and mitochondria studies", The CFIDS Chronicle, winter, 1995.

New England Journal of Medicine, August 31, 1995.

J. Gordon Millichap, "Abnormal EEG in autism: valproate response", Progress in Pediatric Neurology III, pages 126 and 239, 1997.

Bernard Rimland, "IVIG therapy tested in autism, Landau-Kleffner syndrome", Autism Research Review International, spring, 1998.

Ellaway, C., et al. "Rett Syndrome: randomized controlled trial of L-carnitine", Journal of Child Neurology, 14:162-167, 1999.

"Employee spotlight", Marklund Care Letter, summer, 1999.

Milda Budrys, Lithuanian Physicians and Scholars, p. 163-165, 2002.

Gretchen Henkel, "Vest curbs pneumonia in pediatric LTC", Caring for the Ages, January 2003.

Gretchen Henkel, "Progress report: Pediatric CPG", Caring for the Ages, February 2004.

Kathleen K. Frampton, "Chronic neurological disorders throughout the lifespan", Caring for the Ages, August 2005.

Temple Grandin, Thinking in Pictures, p. 124, 2006.

Kathleen K. Frampton, "Medically Fragile Children Challenge Medical Home Concept", Caring for the Ages, January 2006.